HC Wainwright Predicts Cytosorbents Q1 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cytosorbents in a report released on Thursday, April 3rd. HC Wainwright analyst S. Lee anticipates that the medical research company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.11) EPS.

Other research analysts also recently issued reports about the company. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research note on Tuesday, April 1st. StockNews.com started coverage on shares of Cytosorbents in a report on Thursday. They issued a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Down 2.0 %

NASDAQ:CTSO opened at $0.97 on Monday. The firm has a market capitalization of $60.63 million, a PE ratio of -2.69 and a beta of 1.17. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The stock has a 50 day moving average of $1.07 and a 200-day moving average of $1.04.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new stake in shares of Cytosorbents during the fourth quarter valued at about $30,000. Renaissance Technologies LLC raised its position in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after acquiring an additional 16,701 shares during the period. Raymond James Financial Inc. bought a new position in shares of Cytosorbents in the fourth quarter valued at approximately $99,000. Finally, Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the period. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.